The present invention relates to uses of polypeptide compounds having dual agonist effect of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). The polypeptide compounds are characterized by high enzymolysis stability, high biological activity and no adverse reaction, are capable of reducing abnormal increase in total cholesterol in blood induced by diabetes mellitus and high fat diet, reducing liver enzyme level, improving liver injury and fibrosis degree, and may be used to prevent or treat diseases such as non-alcoholic fatty liver diseases (NAFLD), hyperlipemia and arteriosclerosis.本發明涉及一類具有胰高血糖素樣肽-1受體（Glucagon-like peptide-1 receptor，GLP-1R）和胰高血糖素受體（Glucagon receptor，GCGR）雙激動效應的多肽化合物的用途，其具有高酶解穩定性、高生物活性、無不良反應等特點，能夠降低因糖尿病以及高脂膳食誘發的血中總膽固醇和三甘油酯水準異常升高，降低肝酶水準，改善肝臟損傷和纖維化程度，並可用於預防或治療非酒精性脂肪肝病、高脂血症、動脈硬化等疾病。
